{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:55:19Z","timestamp":1779299719509,"version":"3.51.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-024-00929-4","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T13:02:45Z","timestamp":1725973365000},"page":"183-187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effective management of necrotizing crescentic glomerulonephritis using an aggressive combination therapy including avacopan in a patient double-seropositive for anti-GBM antibodies and ANCA: a case report"],"prefix":"10.1007","volume":"14","author":[{"given":"Rina","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Toishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiji","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Aihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumie","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiko","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuro","family":"Kawaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Matsunami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamiko","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5536-1741","authenticated-orcid":false,"given":"Tomo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"929_CR1","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.2215\/CJN.01380217","volume":"12","author":"SP McAdoo","year":"2017","unstructured":"McAdoo SP, Pusey CD. Anti-glomerular basement membrane disease. Clin J Am Soc Nephrol. 2017;12:1162\u201372.","journal-title":"Clin J Am Soc Nephrol"},{"key":"929_CR2","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1093\/ndt\/gfu399","volume":"30","author":"B Alchi","year":"2015","unstructured":"Alchi B, Griffiths M, Sivalingam M, Jayne D, Farrington K. Predictors of renal and patient outcomes in anti-GBM disease: clinicopathologic analysis of a two-centre cohort. Nephrol Dial Transplant. 2015;30:814\u201321.","journal-title":"Nephrol Dial Transplant"},{"key":"929_CR3","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.kint.2017.03.014","volume":"92","author":"SP McAdoo","year":"2017","unstructured":"McAdoo SP, Tanna A, Hru\u0161kov\u00e1 Z, et al. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int. 2017;92:693\u2013702.","journal-title":"Kidney Int"},{"key":"929_CR4","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int. 2021;100:753\u201379.","journal-title":"Kidney Int"},{"key":"929_CR5","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.ekir.2018.12.002","volume":"4","author":"R Jain","year":"2018","unstructured":"Jain R, Dgheim H, Bomback AS. Rituximab for anti-glomerular basement membrane disease. Kidney Int Rep. 2018;4:614\u20138.","journal-title":"Kidney Int Rep"},{"key":"929_CR6","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.kint.2021.08.025","volume":"100","author":"K Gulati","year":"2021","unstructured":"Gulati K, Edwards H, Prendecki M, et al. Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 2021;100:1316\u201324.","journal-title":"Kidney Int"},{"key":"929_CR7","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","volume":"325","author":"S Furuta","year":"2021","unstructured":"Furuta S, Nakagomi D, Kobayashi Y, et al. Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial. JAMA. 2021;325:2178\u201387.","journal-title":"JAMA"},{"key":"929_CR8","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh M, Merkel PA, Peh CA, et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020;382:622\u201331.","journal-title":"N Engl J Med"},{"key":"929_CR9","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne DRW, Merkel PA, Schall TJ, Bekker P, ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384:599\u2013609.","journal-title":"N Engl J Med"},{"key":"929_CR10","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ekir.2022.01.1065","volume":"7","author":"C Gabilan","year":"2022","unstructured":"Gabilan C, Pfirmann P, Ribes D, et al. Avacopan as first-line treatment in antineutrophil cytoplasmic antibody-associated vasculitis: a steroid-sparing option. Kidney Int Rep. 2022;7:1115\u20138.","journal-title":"Kidney Int Rep"},{"key":"929_CR11","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1007\/s40620-023-01614-y","volume":"36","author":"L Alvarez","year":"2023","unstructured":"Alvarez L, Kambham N, Su R. Renal improvement and remission in a patient with refractory ANCA-associated vasculitis treated with avacopan. J Nephrol. 2023;36:2365\u201370.","journal-title":"J Nephrol"},{"key":"929_CR12","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.ekir.2023.05.017","volume":"8","author":"FB Cortazar","year":"2023","unstructured":"Cortazar FB, Cerda J, Dhanani R, Roglieri J, Santoriello D. Avacopan in patients with rapidly progressive glomerulonephritis requiring dialysis. Kidney Int Rep. 2023;8:1687\u201391.","journal-title":"Kidney Int Rep"},{"key":"929_CR13","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ekir.2023.01.039","volume":"8","author":"FB Cortazar","year":"2023","unstructured":"Cortazar FB, Niles JL, Jayne DRW, et al. Renal recovery for patients with ANCA-associated vasculitis and low eGFR in the ADVOCATE trial of avacopan. Kidney Int Rep. 2023;8:860\u201370.","journal-title":"Kidney Int Rep"},{"key":"929_CR14","doi-asserted-by":"crossref","first-page":"1190394","DOI":"10.3389\/fimmu.2023.1190394","volume":"14","author":"P Caillard","year":"2023","unstructured":"Caillard P, Vigneau C, Halimi JM, et al. Prognostic value of complement serum C3 level and glomerular C3 deposits in anti-glomerular basement membrane disease. Front Immunol. 2023;14:1190394.","journal-title":"Front Immunol"},{"key":"929_CR15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2172-14-19","volume":"14","author":"Z Qu","year":"2013","unstructured":"Qu Z, Cui Z, Liu G, Zhao MH. The distribution of IgG subclass deposition on renal tissues from patients with anti-glomerular basement membrane disease. BMC Immunol. 2013;14:19.","journal-title":"BMC Immunol"},{"key":"929_CR16","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1309\/NPTP4UKV7JU3ELMQ","volume":"125","author":"EG Fischer","year":"2006","unstructured":"Fischer EG, Lager DJ. Anti-glomerular basement membrane glomerulonephritis: a morphologic study of 80 cases. Am J Clin Pathol. 2006;125:445\u201350.","journal-title":"Am J Clin Pathol"},{"key":"929_CR17","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1016\/j.ekir.2021.08.005","volume":"6","author":"R Oba","year":"2021","unstructured":"Oba R, Kanzaki G, Sasaki T, et al. Long-term renal survival in antineutrophil cytoplasmic antibody-associated glomerulonephritis with complement C3 deposition. Kidney Int Rep. 2021;6:2661\u201370.","journal-title":"Kidney Int Rep"},{"key":"929_CR18","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/ckj\/sfad030","volume":"16","author":"A Sethi","year":"2023","unstructured":"Sethi A, Grande J, Specks U, Fervenza FC. Proteomic profile of uninvolved versus crescentic glomeruli in MPO-ANCA-associated vasculitis. Clin Kidney J. 2023;16:1180\u20132.","journal-title":"Clin Kidney J"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-024-00929-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-024-00929-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-024-00929-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T03:25:20Z","timestamp":1743650720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-024-00929-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["929"],"URL":"https:\/\/doi.org\/10.1007\/s13730-024-00929-4","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]},"assertion":[{"value":"21 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This case study was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from the participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}